New Oral Selective Estrogen Receptor Degraders Redefine Management of Estrogen Receptor-Positive Breast Cancer.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 39869433.
- Also identified by DOI 10.1146/annurev-med-052423-122001.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Oral selective estrogen receptor degraders (SERDs) are pure estrogen receptor antagonists that have the potential to overcome common resistance mechanisms to endocrine therapy in estrogen receptor-positive breast cancer. There are currently five oral SERDs in published and ongoing clinical trials-elacestrant, camizestrant, giredestrant, imlunestrant, and amcenestrant-with more in development. They offer a reasonably well-tolerated oral therapy option with low discontinuation rates in studies. This review summarizes the currently available literature on this new class of drugs.
Medical subject headings
- Breast Neoplasms
- Selective Estrogen Receptor Modulators
- Receptors, Estrogen
- Antineoplastic Agents, Hormonal